Recurrent Ovarian Endometrioid Adenocarcinoma (DBCOND0113753)

Identifiers

Synonyms
Not Available

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT02446600
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3active_not_recruiting
NCT05231122
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancertreatment2recruiting
NCT04739800
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agentstreatment2active_not_recruiting
NCT02839707
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2 / 3active_not_recruiting
NCT04092270
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancertreatment1recruiting
NCT05920798
A Study of FRaDCs for Ovarian Cancertreatment1 / 2recruiting
NCT03348631
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancertreatment2active_not_recruiting
NCT04034927
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancertreatment2active_not_recruiting
NCT05295589
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapytreatment2withdrawn